Publication: HLA-B*58:01 for allopurinol-induced cutaneous adverse drug reactions: Implication for clinical interpretation in Thailand
| dc.contributor.author | Chonlaphat Sukasem | en_US |
| dc.contributor.author | Thawinee Jantararoungtong | en_US |
| dc.contributor.author | Parnrat Kuntawong | en_US |
| dc.contributor.author | Apichaya Puangpetch | en_US |
| dc.contributor.author | Napatrupron Koomdee | en_US |
| dc.contributor.author | Patompong Satapornpong | en_US |
| dc.contributor.author | Patcharin Supapsophon | en_US |
| dc.contributor.author | Jettanong Klaewsongkram | en_US |
| dc.contributor.author | Ticha Rerkpattanapipat | en_US |
| dc.contributor.other | Mahidol University | en_US |
| dc.contributor.other | Faculty of Medicine, Ramathibodi Hospital, Mahidol University | en_US |
| dc.contributor.other | Thai Severe Cutaneous Adverse Drug Reaction (Thai-SCAR) Research Group | en_US |
| dc.contributor.other | Chulalongkorn University | en_US |
| dc.date.accessioned | 2018-12-11T03:34:28Z | |
| dc.date.accessioned | 2019-03-14T08:02:13Z | |
| dc.date.available | 2018-12-11T03:34:28Z | |
| dc.date.available | 2019-03-14T08:02:13Z | |
| dc.date.issued | 2016-07-18 | en_US |
| dc.description.abstract | © 2016 Sukasem. Background: The aim of this study was to investigate the predisposition to different types of allopurinol-induced cutaneous adverse drug reactions (CADR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN; SJS-TEN, n = 13), drug reaction with eosinophilia and systemic symptoms (DRESS, n = 10) and Maculopapular eruption (MPE; n = 7), conferred by HLA-B*58:01 in a Thai population.Methods: This case-control association study compares 30 patients with allopurinol-induced CADR, allopurinol-tolerant control patients (n = 100), and a Thai general population (n = 1095). Patients' human leukocyte antigen type B (HLA-B) alleles were genotyped by using a two-stage sequence-specific oligonucleotide probe system.Results: Of a total 30 patients with CADR due to allopurinol, 29 (96.7%) patients were found to be at least heterozygous for HLA-B*58:01, compared to only 4.0% in allopurinol-tolerant patients (p < 0.001). Odds ratio (OR) for the association of HLA-B*58:01 with allopurinol-induced CADR in this population was 696.0 (95% CI: 74.8-6475.0). The HLA-B*58:01 allele was present in all patients with allopurinol-induced SJS-TEN (OR = 579.0, 95%CI: 29.5-11362.7, p < 0.001) and DRESS (OR 430.3, 95%CI: 22.6-8958.9, p < 0.001). Additionally, OR of HLA-B*58:01 was highly significant in the allopurinol-induced MPE patients (OR 144.0, 95%CI: 13.9-1497.0, p < 0.001).Conclusion: In this study we confirmed the association between HLAB*58:01 and allopurinol-induced SJS-TEN in a Thai population. In addition, we identified an association between HLA-B*58:01 and allopurinol-induced DRESS and MPE in this population. Therefore, HLA-B*58:01 can be used as a pharmacogenetic marker for allopurinol-induced CADR including SJS-TEN, DRESS and MPE. These results suggest that screening for HLA-B*58:01 alleles in patients who will be treated with allopurinol would be clinically helpful in preventing the risk of developing CARD in a Thai patients. Summary Regardless of phenotype, this is the first pharmacogenetic study of allopurinol-induced CADR in patients of Thai ancestry. In this study we confirmed the association between HLA-B*58:01 and allopurinol-induced SJS-TEN, DRESS, and MPE in Thai population. Regarding to our findings, the pharmacogenetic interpretation could be generalized to drug hypersensitivity including DRESS, SJS-TEN, and MPE. | en_US |
| dc.identifier.citation | Frontiers in Pharmacology. Vol.7, No.JUL (2016) | en_US |
| dc.identifier.doi | 10.3389/fphar.2016.00186 | en_US |
| dc.identifier.issn | 16639812 | en_US |
| dc.identifier.other | 2-s2.0-84981502021 | en_US |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/41280 | |
| dc.rights | Mahidol University | en_US |
| dc.rights.holder | SCOPUS | en_US |
| dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84981502021&origin=inward | en_US |
| dc.subject | Medicine | en_US |
| dc.title | HLA-B*58:01 for allopurinol-induced cutaneous adverse drug reactions: Implication for clinical interpretation in Thailand | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84981502021&origin=inward | en_US |
